Statin Use and the Risk of Subsequent Hospitalized Exacerbations in COPD Patients with Frequent Exacerbations

References

• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• GroenewegenKH, ScholsAM, WoutersEF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124(2):459–467. doi:10.1378/chest.124.2.45912907529
   PubMed Web of Science ®Google Scholar
• MiravitllesM, FerrerM, PontA, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59(5):387–395. doi:10.1136/thx.2003.00873015115864
   PubMed Web of Science ®Google Scholar
• SinganayagamA, SchembriS, ChalmersJD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(2):81–89. doi:10.1513/AnnalsATS.201208-043OC23607835
   PubMedGoogle Scholar
• SuissaS, Dell’AnielloS, ErnstP. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. doi:10.1136/thoraxjnl-2011-20151822684094
   PubMed Web of Science ®Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJ, Martinez-GarciaMA, Roman SanchezP, SalcedoE, NavarroM, OchandoR. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.04052716055622
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, SeemungalTA, BhowmikA, WedzichaJA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.84712324669
   PubMed Web of Science ®Google Scholar
• Nussbaumer-OchsnerY, RabeKF. Systemic manifestations of COPD. Chest. 2011;139(1):165–173. doi:10.1378/chest.10-125221208876
   PubMed Web of Science ®Google Scholar
• FabbriLM, RabeKF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370(9589):797–799. doi:10.1016/S0140-6736(07)61383-X17765529
   PubMed Web of Science ®Google Scholar
• AgustiA. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should). Proc Am Thorac Soc. 2007;4(7):522–525. doi:10.1513/pats.200701-004FM17878464
   PubMedGoogle Scholar
• PereraWR, HurstJR, WilkinsonTM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007;29(3):527–534. doi:10.1183/09031936.0009250617107990
   PubMed Web of Science ®Google Scholar
• KinlayS, SchwartzGG, OlssonAG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108(13):1560–1566. doi:10.1161/01.CIR.0000091404.09558.AF12975259
   PubMed Web of Science ®Google Scholar
• InoueI, GotoS, MizotaniK, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 2000;67(8):863–876. doi:10.1016/s0024-3205(00)00680-910946846
   PubMed Web of Science ®Google Scholar
• DavignonJ. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol. 2012;73(4):518–535. doi:10.1111/bcp.2012.73.issue-422053916
   PubMed Web of Science ®Google Scholar
• WangCY, LiuPY, LiaoJK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37–44. doi:10.1016/j.molmed.2007.11.00418068482
   PubMed Web of Science ®Google Scholar
• HothersallE, McSharryC, ThomsonNC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006;61(8):729–734. doi:10.1136/thx.2005.05797616877692
   PubMed Web of Science ®Google Scholar
• BellostaS, ViaD, CanavesiM, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18(11):1671–1678. doi:10.1161/01.ATV.18.11.16719812903
   PubMed Web of Science ®Google Scholar
• RidkerPM, DanielsonE, FonsecaFA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. doi:10.1056/NEJMoa080764618997196
   PubMed Web of Science ®Google Scholar
• BrugtsJJ, YetginT, HoeksSE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. doi:10.1136/bmj.b237619567909
   PubMed Web of Science ®Google Scholar
• TaylorF, WardK, MooreTH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816.
   Google Scholar
• WangMT, LoYW, TsaiCL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med. 2013;126(7):598–606 e592. doi:10.1016/j.amjmed.2013.01.03623684060
   PubMed Web of Science ®Google Scholar
• BlamounAI, BattyGN, DeBariVA, RashidAO, SheikhM, KhanMA. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62(9):1373–1378. doi:10.1111/j.1742-1241.2008.01731.x18422598
   PubMed Web of Science ®Google Scholar
• HuangCC, ChanWL, ChenYC, et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. Clin Ther. 2011;33(10):1365–1370. doi:10.1016/j.clinthera.2011.08.01021962452
   PubMed Web of Science ®Google Scholar
• AjmeraM, ShenC, SambamoorthiU. Association between statin medications and COPD-specific outcomes: a real-world observational study. Drugs Real World Outcomes. 2017;4(1):9–19. doi:10.1007/s40801-016-0101-627943058
   PubMedGoogle Scholar
• RaymakersAJN, SadatsafaviM, SinDD, De VeraMA, LyndLD. The impact of statin drug use on all-cause mortality in patients with COPD: a population-based cohort study. Chest. 2017;152(3):486–493. doi:10.1016/j.chest.2017.02.00228202342
   PubMed Web of Science ®Google Scholar
• SoysethV, BrekkePH, SmithP, OmlandT. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279–283. doi:10.1183/09031936.0010640617050558
   PubMed Web of Science ®Google Scholar
• LawesCM, ThornleyS, YoungR, et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Primary Care Respir j. 2012;21(1):35–40. doi:10.4104/pcrj.2011.0009522218819
   PubMedGoogle Scholar
• LahousseL, LothDW, JoosGF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther. 2013;26(2):212–217. doi:10.1016/j.pupt.2012.10.00823142156
   PubMed Web of Science ®Google Scholar
• IngebrigtsenTS, MarottJL, NordestgaardBG, LangeP, HallasJ, VestboJ. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33–40. doi:10.1136/thoraxjnl-2014-20579525349333
   PubMed Web of Science ®Google Scholar
• CrinerGJ, ConnettJE, AaronSD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201–2210. doi:10.1056/NEJMoa140308624836125
   PubMed Web of Science ®Google Scholar
• AustinPC, FineJP. Practical recommendations for reporting fine-gray model analyses for competing risk data. Stat Med. 2017;36(27):4391–4400. doi:10.1002/sim.v36.2728913837
   PubMed Web of Science ®Google Scholar
• YoungRP, HopkinsRJ, AgustiA. Statins as adjunct therapy in COPD: how do we cope after STATCOPE? Thorax. 2014;69(10):891–894. doi:10.1136/thoraxjnl-2014-20581425015240
   PubMed Web of Science ®Google Scholar
• ManciniGB, RoadJ. Are statins out in the COLD? The STATCOPE trial. Can J Cardiol. 2015;31(8):970–973. doi:10.1016/j.cjca.2015.03.01626117620
   PubMed Web of Science ®Google Scholar
• DormuthCR, PatrickAR, ShrankWH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119(15):2051–2057. doi:10.1161/CIRCULATIONAHA.108.82415119349320
   PubMed Web of Science ®Google Scholar